1:00 p.m. | Registration
1:30 p.m. | Welcome Remarks
Uciane Scarlett, Host
1:40 p.m. | Research: What’s likely to shape the innovation funnel
(fire-side chat – 40 mins)
John Connolly, PhD - CSO, Parker Institute for Cancer Immunotherapy (PICI)
Moderator: Uciane Scarlett, PhD - former principal, MPM BioImpact
2:20 p.m. | Innovation Bridge: Oncology Bull and Bear Cases
Ricardo Brau, PhD - Managing Director & Partner, L.E.K.
Lain Anderson - Managing Director & Co-Head of Americas Healthcare Sector, L.E.K.
2:50 p.m. | Innovation: Optimal approach for 2025 - watch & wait vs strategic bets
(debate-style panel – 60 mins)
Alexis Borisy - Operating Chairman, Curie.Bio
Irina Margine, PhD - Biotech Sector Lead, Wellington Management
Jean-François Formela, MD - Partner, Atlas Ventures
Keith Flaherty, MD - Professor, MGH; Co-founder Loxo Oncology, Scorpion Therapeutics
Errik Anderson - CEO, Alloy Tx, GP, 82VS
Joe Pearlberg, MD, PhD - VP of Scientific Affairs, Deerfield Management
Moderator: Prashant Girinath, PhD- Shareholder, Greenberg Traurig
3:50 p.m. | People: Stakeholders and their value cycles
(round table – 60 mins)
Micah Benson, PhD - CSO, KSQ
Paulina Hill, PhD – Partner, Sanofi Ventures
Colin Hill, M.S - CEO, Co-founder, Aitia Bio
Stephanie Oestreich, PhD, MPA - Managing Director, Myeloma Investment Fund
Tim Clackson, PhD - CEO, IDRx
Moderator: Luba Greenwood, J.D. - CEO, Gallop Onc, EiR PureTech
4:50 p.m. | Closing Remarks
Yung Lie, PhD - President & CEO, Damon Runyon
John Connolly, PhD - CSO, Parker Institute for Cancer Immunotherapy, PICI
5:00-8:00 p.m. | Greenberg Traurig hosted Reception at Catalyst